List of Uzedy drug patents
Uzedy is owned by Teva.
Uzedy contains Risperidone.
Uzedy has a total of 8 drug patents out of which 0 drug patents have expired.
Uzedy was authorised for market use on 28 April, 2023.
Uzedy is available in suspension, extended release;subcutaneous dosage forms.
Uzedy can be used as treatment of schizophrenia.
The generics of Uzedy are possible to be released after 12 November, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9895447 | TEVA | Drug-containing PLA implants and methods of use thereof |
Jan, 2025
(1 year, 7 months from now) | |
| US9717799 | TEVA | Drug-containing implants and methods of use thereof |
Jan, 2025
(1 year, 7 months from now) | |
| US9439905 | TEVA | Risperidone-containing implants and methods of use thereof |
Jan, 2025
(1 year, 7 months from now) | |
| US9925268 | TEVA | Drug-containing implants and methods of use thereof |
Jan, 2025
(1 year, 7 months from now) | |
| US10736965 | TEVA | Risperidone biodegradable implant |
Jan, 2025
(1 year, 7 months from now) | |
| US8802127 | TEVA | Risperidone-containing PLA:PGA implants and methods of use thereof |
Jan, 2025
(1 year, 7 months from now) | |
| US8221778 | TEVA | Drug-containing implants and methods of use thereof |
Nov, 2027
(4 years from now) | |
| US8741327 | TEVA | Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant |
Nov, 2027
(4 years from now) | |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic